HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
HPPI's patent portfolio expands again with claims covering treatment of any non-cancerous proliferation disorders with itraconazole, the active ingredient in HPPI's current and anticipated fut...
Page (1) of 1 - 05/21/18||
(May 21, 2018)
This article is no longer available,but here are some related topics.
USA, Inc.,Science,Communications Technology,Medical,Cancer,Other,
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved